Brief: Schrodinger Q2 Software Revenue USD 40.5 Million

Schrodinger

06/08/2025 21:05

Overview

Schrodinger Q2 2025 rev rises 16% to $54.8 mln, beating analyst expectations

Company maintains full-year 2025 revenue growth guidance, lowers operating expense guidance

Initial clinical data for SGR-3515 and SGR-2921 expected in Q4 2025

Outlook

Schrödinger expects 2025 software revenue growth of 10% to 15%

Company forecasts drug discovery revenue of $45 mln to $50 mln in 2025

Software gross margin for 2025 expected to be 74% to 75%

Operating expenses in 2025 expected to be lower than 2024

Result Drivers

SOFTWARE REVENUE - Increase driven by hosted contracts and contribution revenue, partially offset by prior multi-year on-premise contracts

DRUG DISCOVERY REVENUE - Growth attributed to increased activity in drug discovery segment

LOWER OPERATING EXPENSES - Decrease due to reduced R&D expenses

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$54.80 mln
$52 mln (8 Analysts)
Q2 Net Income
-$43.20 mln
Q2 Software Gross Margin
68.0%
Q2 Gross Profit
$26.16 mln
Q2 Operating Expenses
$79.10 mln
Q2 Software Revenue
$40.50 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the software peer group is "buy"

Wall Street's median 12-month price target for Schrodinger Inc is $31.00, about 36.6% above its August 5 closing price of $19.64

Press Release: ID:nBw6zMNcJa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)